Akari Therapeutics PLC (NASDAQ:AKTX – Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $11.83 and traded as low as $3.02. Akari Therapeutics shares last traded at $3.06, with a volume of 106,626 shares.
Analyst Ratings Changes
Several analysts have recently commented on AKTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Monday, April 20th. HC Wainwright upped their price target on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. Finally, Maxim Group lowered Akari Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $89.00.
Check Out Our Latest Stock Report on AKTX
Akari Therapeutics Stock Down 40.6%
Akari Therapeutics (NASDAQ:AKTX – Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The biopharmaceutical company reported ($2.68) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($2.65).
Institutional Investors Weigh In On Akari Therapeutics
A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC acquired a new stake in Akari Therapeutics PLC (NASDAQ:AKTX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics at the end of the most recent quarter. Institutional investors own 5.06% of the company’s stock.
About Akari Therapeutics
Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.
Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.
Read More
- Five stocks we like better than Akari Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
